Why the study?
Major bleeding occurs in 1 to 3% of patients treated with oral anticoagulants annually, and soluble thrombomodulin was proposed as a biomarker to help identify high-risk patients.
Do high soluble thrombomodulin levels increase the risk of major bleeding in patients treated with vitamin K antagonists?
Population
326 patients with a major bleed and a random sample of 652 individuals from the BLEEDS cohort starting vitamin K antagonists
Comparison
Plasma sTM levels stratified by percentiles
Design
Case-cohort study
Authors
Loading...
May support sTM as bleeding risk marker before VKA initiation; leaves open prospective validation before clinical use.
Do high soluble thrombomodulin levels increase the risk of major bleeding in patients treated with vitamin K antagonists?
High soluble thrombomodulin levels at the start of vitamin K antagonist treatment are associated with an increased risk of major bleeding, especially when INR is high.
Toorop et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: